Akkermansia muciniphila (pasteurized)
Also called: A. muciniphila, pasteurised Akkermansia muciniphila, Akkermansia muciniphila MucT, A. muciniphila ATCC BAA-835
Akkermansia muciniphila is a Gram-negative, strictly anaerobic, mucin-degrading human gut bacterium. The form EFSA assessed as a novel food is the pasteurized strain MucT (ATCC BAA-835), with viable cells required to be below 10 CFU/g. Results here are strain-specific.
- Category
- Probiotic
- Forms
- Pasteurized bacterial cells (EFSA condition: fewer than 10 viable CFU/g); amounts stated in cells per day
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-30
Class 3 Limited studies in people. Counted per strain (evidence is strain-specific): MucT has 2 randomized placebo-controlled trials (2019, 32 completers; 2026, 90 adults) plus a 142-adult placebo-controlled trial not stated as randomized; HB05P (2024) and AKK-WST01 (2025) have one RCT each. No review stating a count was found. [4]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBlood sugar and weight4 topics
CMuscles and exercise1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Insulin sensitivity and metabolic markers in overweight or obese insulin-resistant adults | C | In a 3-month pilot RCT (40 enrolled, 32 completed), pasteurized A. muciniphila (10^10 bacteria/day) improved insulin sensitivity (+28.6%) and lowered insulinemia and total cholesterol versus placebo; body-weight change was not significant. [3] |
| Weight regain after diet-induced weight loss | C | In an RCT of 90 adults with overweight or obesity, 24 weeks of pasteurized MucT after an 8-week low-energy diet led to less weight regain than placebo (1.2 vs 3.2 kg). [4] |
| Whole-body insulin sensitivity in adults with metabolic syndrome | X | In a double-blind placebo-controlled trial of 142 adults, 4 months of pasteurized MucT (30 billion cells/day) did not change the primary endpoint (Matsuda index); benefits appeared only in exploratory subgroups. [5] |
| Body weight and HbA1c in overweight or obese type 2 diabetes (strain AKK-WST01) | C | In a 12-week RCT of 58 participants, live AKK-WST01 did not differ from placebo in body weight or HbA1c overall; reductions appeared only in those with low baseline A. muciniphila. It does not apply directly to pasteurized products. [6] |
| Muscle strength in adults aged 60 or older (pasteurized strain HB05P) | C | In a 12-week double-blind RCT of 100 adults, pasteurized HB05P (1.0 x 10^10 cells/day) improved left-leg extensor peak torque versus placebo. [7] |
Main constituents: Akkermansia muciniphila MucT (ATCC BAA-835T = CIP 107961T); whole genome sequenced (NCBI NC_010655.1) [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Pilot RCT: 10^10 A. muciniphila bacteria per day, live or pasteurized, for three months. [3]
- Metabolic syndrome trial: capsules with 30 billion cells of pasteurized MucT daily for 4 months. [5]
- Older-adult muscle trial: 1.0 x 10^10 cells/day of pasteurized HB05P for 12 weeks. [7]
Upper limits
- EU (EFSA, 2021): "the consumption of 3.4 × 10^10 cells/day is safe for the target population under the provision that the number of viable cells in the NF is < 10 colony forming units (CFU)/g"; the target population is "the general adult population excluding pregnant and lactating women". The level applies an uncertainty factor of 200 to the NOAEL of a 90-day rat study. [1]
- EU (EFSA, 2025): pasteurised A. muciniphila "is safe at doses up to 2.1 × 10^10 cells/day for adolescents from 12 to < 14 years and 3.0 × 10^10 cells/day for adolescents from 14 years until < 18 years." [2]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingEFSA (2025): "no evidence was provided for the safety of the NF in pregnant and lactating women" and "The safety of the NF in pregnant and lactating …
1 statement in the profile.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications4 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- EFSA describes A. muciniphila as a well-characterized, non-toxin-producing, avirulent microorganism reported as part of normal gut microbiota. [1]
- EFSA (2025): "no evidence was provided for the safety of the NF in pregnant and lactating women" and "The safety of the NF in pregnant and lactating women has not been established." [2]
- In the pilot RCT, three months of daily live or pasteurized A. muciniphila was safe and well tolerated. [3]
- In the 90-adult weight-maintenance RCT, no serious treatment-related adverse events were observed. [4]
Identity, quality and standardization
Regulatory status
- EU: EFSA's NDA Panel concluded in 2021 that pasteurized A. muciniphila, proposed for food supplements and foods for special medical purposes, is safe for the target population under the stated conditions. [1]
- EU: In 2025 EFSA concluded that an extension of use to adolescents aged 12 to under 18 is safe at the stated doses; safety in pregnancy and lactation was not established. [2]
- US: FDA's published NDI notification list has 4 entries naming Akkermansia muciniphila (earliest NDI 1326 submitted 2024-03-11; most recent NDI 1438 submitted 2025-09-22). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [9]
- US: No GRAS notice naming Akkermansia muciniphila was found in FDA's GRAS Notice Inventory (checked 2026-10-30). [10]
- Canada: A. muciniphila is not among the organisms in Health Canada's probiotics monograph (April 24, 2026), which also excludes non-viable (for example heat-killed) forms of its listed organisms. [8]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [11]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Pasteurized Akkermansia muciniphila MucT (ATCC BAA-835T) Inactivated gut bacterium (Gram-negative, strictly anaerobic) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 4 entries naming Akkermansia muciniphila (earliest NDI 1326 submitted 2024-03-11; most recent NDI 1438 submitted 2025-09-22). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P3]
- No GRAS notice naming Akkermansia muciniphila was found in FDA's GRAS Notice Inventory (checked 2026-10-30). [P4]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of Akkermansia muciniphila was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-30). [P5]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P7]
- Absence of viable cells (below 10 CFU/g) — EFSA's safety conclusion for pasteurized A. muciniphila is conditional on viable cells being below the 10 CFU/g limit of detection. [P1]
- Strain identity by whole-genome sequencing — EFSA confirmed strain MucT's identity by whole-genome sequence and phylogenetic analyses. [P1]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- EFSA (2025): "no evidence was provided for the safety of the NF in pregnant and lactating women" and "The safety of the NF in pregnant and lactating women has not been established." [P2]
Sources for this profile
- EFSA NDA Panel. Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2021;19(9):e06780 (PMID 34484452; full text PMC8409316), 2021-09-01. pmc.ncbi.nlm.nih.gov
- EFSA NDA Panel. Safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2025;23(9):e9632 (PMID 41018002), 2025-09-25. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory (searchable list, checked 2026-10-30), 2026-10-30. hfpappexternal.fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- EFSA NDA Panel. Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2021;19(9):e06780 (PMID 34484452; full text PMC8409316), 2021-09-01. pmc.ncbi.nlm.nih.gov
- EFSA NDA Panel. Safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2025;23(9):e9632 (PMID 41018002), 2025-09-25. pubmed.ncbi.nlm.nih.gov
- Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 2019;25(7):1096-1103 (PMID 31263284), 2019-07. pubmed.ncbi.nlm.nih.gov
- Mount S, et al. Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nat Med 2026;32(6):2107-2116 (PMID 42120725), 2026-06. pubmed.ncbi.nlm.nih.gov
- Suenaert P, et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut Microbes 2026;18(1):2690689 (PMID 42343233), 2026-06-24. pubmed.ncbi.nlm.nih.gov
- Zhang Y, et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: efficacy depends on its baseline levels in the gut. Cell Metab 2025;37(3):592-605 (PMID 39879980), 2025-03-04. pubmed.ncbi.nlm.nih.gov
- Kang CH, et al. Pasteurized Akkermansia muciniphila HB05 (HB05P) improves muscle strength and function: a 12-week, randomized, double-blind, placebo-controlled clinical trial. Nutrients 2024;16(23):4037 (PMID 39683431), 2024-11-26. pubmed.ncbi.nlm.nih.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory (searchable list, checked 2026-10-30), 2026-10-30. hfpappexternal.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in probiotic: Bacillus coagulans (Heyndrickxia coagulans) · Bifidobacterium animalis subsp. lactis BB-12 · Escherichia coli Nissle 1917 (EcN) · Lacticaseibacillus paracasei strain Shirota (LcS) · Lacticaseibacillus rhamnosus GG (LGG) · Lactiplantibacillus plantarum 299v · Limosilactobacillus reuteri DSM 17938 · Probiotics · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.